CAYENNE LAW

Some of Jerry Marr's prior Life Sciences representations

• Ophthotech in its >$1 billion ex-US licensing and commercialization agreement for FOVISTA™ with Novartis
   

• A biopharmaceutical client in a >$1 billion oral diabetes drug collaboration with a global pharmaceutical company
   

• A biopharmaceutical client in a >$1 billion worldwide hepatitis C collaboration with a global pharmaceutical company
   

• A global pharmaceutical client in a >$1 billion deal licensing a prostate cancer immunotherapy from an international biotechnology company
   

• An antibody discovery technology client in platform licensing agreements with four global pharmaceutical companies
   

• Two major universities in the spin out and formation of a major biomedical and genomic research institute
   

• A biopharmaceutical client in a spinal muscular atrophy collaboration with a global pharmaceutical company and a charitable foundation
   

• A biopharmaceutical client in license and research agreements with a major hospital for orphan drug candidates